Adding simvastatin to standard therapy offers no benefit over placebo for treatment-resistant depression, a new randomized clinical trial shows.

Prenatal statin use may pose a risk for preterm birth, but not congenital anomalies, a study from Taiwan including more than 1.4 million pregnant women indicates.

Moderate walking program did not affect objective muscle injury measures or pain level

Final data from the REPRIEVE trial show pitavastatin therapy is associated with a significantly lower risk of cardiovascular events than placebo as evidence grows for statins in primary prevention.

Intensive statin therapy immediately after mild ischemic stroke or high-risk TIA reduces the risk for a poor functional outcome vs delaying 72 hours, the INSPIRES trial shows.

Although high-intensity statin use increased when clinicians received prescribing reminders, 31% of those receiving reminders dropped out of the trial, suggesting that alert fatigue remains a concern.

Use of an app to determine eligibility for a statin without a prescription could expand treatment and lead to a reduction in CV events, the TACTiC trial suggests.

Risk factors for statin intolerance include female sex, obesity, hypothyroidism, diabetes, antiarrhythmics, alcohol use, exercise, chronic liver disease, and chronic kidney failure, studies suggest.

Nonprescription rosuvastatin pans out in a second trial

The new statement invites comparison with the more comprehensive 2018 ACC/AHA-multisociety statin guidelines. A slew of editorials across several journals do just that.

Add-on treatment may, however, benefit patients with less advanced liver disease.

In contrast, a larger but less diverse study found cholesterol-lowering drugs protective

The statement recommends strategies to help patients stay on statin medications and suggests alternatives that can be used in patients who really cannot tolerate statins.

A national database analysis finds that disparities in primary-prevention statin use persist despite 10-year atherosclerotic cardiovascular disease risk.

A novel quality improvement project suggests that opportunistic screening with previously performed imaging can be leveraged to improve risk prediction and quality of care.

Expanded prescribing guidelines have not boosted statin use among patients who are at risk for atherosclerotic cardiovascular disease.

Using artificial intelligence to analyze large amounts of information from social media platforms generated novel insights into public perceptions about statins, results of a new study show.

Adding simvastatin to an antidepressant didn't reduce symptoms by week 12, randomized trial found

Yet the good clinical data are complicated by real-world cost and access problems

Interim data from the REPRIEVE study showed that a daily statin cut the risk for cardiovascular events by 35% in adults with HIV at low to moderate CV risk.